AU3714499A - Hepatitis c virus mimotopes - Google Patents

Hepatitis c virus mimotopes

Info

Publication number
AU3714499A
AU3714499A AU37144/99A AU3714499A AU3714499A AU 3714499 A AU3714499 A AU 3714499A AU 37144/99 A AU37144/99 A AU 37144/99A AU 3714499 A AU3714499 A AU 3714499A AU 3714499 A AU3714499 A AU 3714499A
Authority
AU
Australia
Prior art keywords
mimotopes
hepatitis
virus
virus mimotopes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU37144/99A
Inventor
Veronique Barban
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Original Assignee
Pasteur Merieux Serum et Vaccines SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Merieux Serum et Vaccines SA filed Critical Pasteur Merieux Serum et Vaccines SA
Publication of AU3714499A publication Critical patent/AU3714499A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU37144/99A 1998-05-14 1999-05-14 Hepatitis c virus mimotopes Abandoned AU3714499A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9806335 1998-05-14
FR9806335 1998-05-14
PCT/FR1999/001155 WO1999058561A1 (en) 1998-05-14 1999-05-14 Hepatitis c virus mimotopes

Publications (1)

Publication Number Publication Date
AU3714499A true AU3714499A (en) 1999-11-29

Family

ID=9526521

Family Applications (1)

Application Number Title Priority Date Filing Date
AU37144/99A Abandoned AU3714499A (en) 1998-05-14 1999-05-14 Hepatitis c virus mimotopes

Country Status (2)

Country Link
AU (1) AU3714499A (en)
WO (1) WO1999058561A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69937364T2 (en) * 1998-10-23 2008-07-17 Institute Of Virology MN GENE AND PROTEIN
US20030108539A1 (en) * 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
CA2409287A1 (en) * 2000-06-02 2001-12-13 Merck & Co., Inc. Hepatitis c virus conjugates
CN1455866A (en) * 2000-11-03 2003-11-12 肯顿有限公司 Detection of infectious agents using antigen mmics
US7803749B2 (en) * 2002-01-09 2010-09-28 Xigen Sa Peptide inhibitors of MKK7 kinase binding to insulin binding proteins
FR2848566A1 (en) * 2002-12-11 2004-06-18 Centre Nat Rech Scient New peptides recognized by autoantibodies against human thyroperoxidase, useful for diagnosis and treatment of autoimmune diseases and thyoid cancer, also antibodies specific for them
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
US20100297607A1 (en) 2009-05-20 2010-11-25 Jian Zheng Reagents For HCV Antigen-Antibody Combination Assays
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
JP5857056B2 (en) 2010-10-14 2016-02-10 ザイジェン インフラメーション エルティーディー Use of cell penetrating peptide inhibitors of the JNK signaling pathway to treat chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
CN105307670A (en) 2013-06-26 2016-02-03 埃克西金炎症有限公司 New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885768A (en) * 1988-06-17 1999-03-23 The United States Of America As Represented By The Department Of Health And Human Services Hepatitis E virus peptide antigen and antibodies
ES2255068T5 (en) * 1990-11-03 2010-08-03 Siemens Healthcare Diagnostics Products Gmbh SPECIFIC PEPTIDES FOR HCV, ITS AGENTS AND ITS USE.
DK0489968T3 (en) * 1990-12-14 1997-03-24 Innogenetics Nv Synthetic antigens for detection of antibodies against hepatitis C virus
FR2690921B1 (en) * 1992-05-06 1995-06-30 Bio Merieux SYNTHESIS POLYPEPTIDES BELONGING TO HEPATITIS C VIRUS (HCV) AND USED IN PARTICULAR FOR DETECTING THE SAME.
EP0992581B2 (en) * 1993-11-04 2011-05-25 Innogenetics N.V. Immunodominant human T-cell epitopes of hepatitis C virus
CA2166313A1 (en) * 1994-02-14 1995-08-17 John N. Simons Non-a, non-b, non-c, non-d, non-e hepatitis reagents and methods for their use
JP3756974B2 (en) * 1995-07-20 2006-03-22 株式会社エスアールエル Method for determining the effectiveness of treatment of genotype 1b against hepatitis C virus
FR2744725B1 (en) * 1996-02-09 1998-04-30 Pasteur Institut SPECIFIC ANTIBODIES OF COMPLEXES FORMED BY GLYCOPROTEINS E1 AND E2 OF THE HEPATITIS C VIRUS, METHODS FOR DETERMINING THE PRESENCE, AND ISOLATION OF THESE COMPLEXES
CA2250723C (en) * 1996-05-24 2012-07-17 Chiron Corporation Multiple epitope fusion protein
EP0937253A1 (en) * 1996-10-31 1999-08-25 Novalon Pharmaceutical Corporation Identification of drugs using complementary combinatorial libraries

Also Published As

Publication number Publication date
WO1999058561A1 (en) 1999-11-18

Similar Documents

Publication Publication Date Title
AU2064297A (en) Hepatitis c virus ribozymes
AU2550995A (en) Hepatitis c virus asialoglycoproteins
AU3714499A (en) Hepatitis c virus mimotopes
AU5285899A (en) Anti hepatitis c virus antibody and uses thereof
AU2001282528A1 (en) Compounds having anti-hepatitis c virus effect
AU6304996A (en) Vaccines against hepatitis c
AU4545199A (en) Bubble trap chamber
AU6703998A (en) Cyclonic filter assembly
AU6445798A (en) Feline immunodeficiency virus clone jsy3
AU4554899A (en) Novel hepatitis c virus peptides and uses thereof
AU1773099A (en) Materials for virus capture
AU6362198A (en) Improved catch basin
IL139269A0 (en) Hepatitis vaccine
AU5216198A (en) Transgenic virus
GB9809666D0 (en) Modified viruses
AU6221996A (en) Oligonucleotides specific for hepatitis c virus
AU9766998A (en) Sand trap
AU4399197A (en) Hepatitis c virus epitope
AU7334498A (en) Hepatitis b virus mutations
HUP0003511A3 (en) Hepatitis b virus polypeptides
AU1093600A (en) Stapedial-saccular strut
AU2100300A (en) Hepatitis y virus
AU1991095A (en) Activating virus
AU2691400A (en) Virus vector
GB9811172D0 (en) Virus production

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase